Zhu Jiayu, Yin Sihan, Luo Shengping, Yu Fei, Sun Kewei
The First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Department of Hepatology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Drug Des Devel Ther. 2025 Aug 19;19:7069-7087. doi: 10.2147/DDDT.S535244. eCollection 2025.
Hepatocellular carcinoma (HCC) is a malignant tumor of the liver. Treatment programs according to its physiological and pathological characteristics have reduced the number of new cases and deaths of HCC, but the morbidity and mortality are still high, posing a significant threat to human health. In recent years, the importance of mitophagy in the treatment of HCC has gradually been recognized. The activation of mitophagy inhibits the survival, proliferation and migration of HCC cells through a variety of pathways, promotes cell apoptosis, and can also reduce drug resistance, providing a new direction for the treatment of HCC. Studies have shown that Traditional Chinese medicine (TCM) monomers and their derivatives can improve the therapeutic efficacy of HCC and slow down disease progression by regulating mitophagy. This article summarizes the potential mechanism of mitophagy in the progression of HCC and comprehensively explores the potential of TCM monomers and their derivatives in the treatment of HCC, providing new perspectives and strategies for clinical treatment.
肝细胞癌（HCC）是一种肝脏恶性肿瘤。根据其生理和病理特征制定的治疗方案已减少了HCC的新发病例数和死亡人数，但发病率和死亡率仍然很高，对人类健康构成重大威胁。近年来，线粒体自噬在HCC治疗中的重要性逐渐得到认可。线粒体自噬的激活通过多种途径抑制HCC细胞的存活、增殖和迁移，促进细胞凋亡，还能降低耐药性，为HCC的治疗提供了新方向。研究表明，中药单体及其衍生物可通过调节线粒体自噬提高HCC的治疗效果并减缓疾病进展。本文总结了线粒体自噬在HCC进展中的潜在机制，并全面探讨了中药单体及其衍生物在HCC治疗中的潜力，为临床治疗提供新的视角和策略。
